EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma. Issue 8 (20th May 2016)

• Record Type: Journal Article
• Authors: Caudron, Anne; Battistella, Maxime; Feugeas, Jean‐Paul; Pages, Cécile; Basset‐Seguin, Nicole; Mazouz Dorval, Sarra; Funck Brentano, Elisa; Sadoux, Aurélie; Podgorniak, Marie‐Pierre; Menashi, Suzanne; Janin, Anne; Lebbé, Céleste; Mourah, Samia
• Is Part Of: Experimental dermatology. Volume 25:Issue 8(2016)
• Page Start: 618
• Page End: 622
• Publication Date: 2016-05-20
• Subjects: disease‐free survival -- invasion -- melanoma progression -- metastasis -- overall survival; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.13022
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: CD147 has been implicated in melanoma invasion and metastasis mainly through increasing metalloproteinase synthesis and regulating VEGF/VEGFR signalling. In this study, the prognostic value of CD147 expression was investigated in a cohort of 196 cutaneous melanomas including 136 consecutive primary malignant melanomas, 30 lymph nodes, 16 in‐transit and 14 visceral metastases. A series of 10 normal skin, 10 blue nevi and 10 dermal nevi was used as control. CD147 expression was assessed by immunohistochemistry, and the association of its expression with the clinicopathological characteristics of patients and survival was evaluated using univariate and multivariate statistical analyses. Univariate analysis showed that high CD147 expression was significantly associated with metastatic potential and with a reduced overall survival ( P < 0.05 for both) in primary melanoma patients. CD147 expression level was correlated with histological factors which were associated with prognosis: Clark level, ulceration status and more particularly with Breslow index ( r = 0.7, P < 10 −8 ). Multivariate analysis retained CD147 expression level and ulceration status as predicting factors for metastasis and overall survival ( P < 0.05 for both). CD147 emerges as an important factor in the aggressive behaviour of melanoma and deserves further evaluation as an independent prognostic biomarker.